KYMR
Kymera Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$6.95B
P/E Ratio
—
EPS
$-3.69
Beta
2.29
52W High
$103.00
52W Low
$20.25
50-Day MA
$81.32
200-Day MA
$63.30
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Kymera Therapeutics Inc
Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins by harnessing the body's own natural protein breakdown system. The company is headquartered in Watertown, Massachusetts.
Fundamentals
| Revenue (TTM) | $39.21M |
| Gross Profit (TTM) | $-277.36M |
| EBITDA | $-338.83M |
| Operating Margin | -3411.00% |
| Return on Equity | -25.80% |
| Return on Assets | -15.90% |
| Revenue/Share (TTM) | $0.46 |
| Book Value | $19.42 |
| Price-to-Book | 4.41 |
| Price-to-Sales (TTM) | 177.19 |
| EV/Revenue | 158.13 |
| EV/EBITDA | -9.49 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -61.20% |
| Shares Outstanding | $81.64M |
| Float | $54.44M |
| % Insiders | 2.22% |
| % Institutions | 110.50% |
Analyst Ratings
Consensus ($119.14 target)
5
Strong Buy16
Buy1
HoldData last updated: 4/8/2026